BAX — Baxter International Inc.

The news flow and the tape disagree. News was good: Q2 2026 sales rose 5% reported and organic to $2.96B, adjusted EPS came in at $0.56 against a $0.37-$0.54 consensus range, FY2026 guidance was raised to $1.95-$2.15 adjusted EPS on 3-4% reported growth, and several firms lifted targets afterward (TD Cowen $24 to $29, Stifel to $28, Citigroup up to Neutral with a $28 target). Yet as of 2026-09-13 the stock had fallen 7.86% in a week and 11.69% in a month. The market's skepticism is about beat QUALITY, not beat size: the guidance raise leaned on a non-recurring tariff refund benefit, Q2 2026 free cash flow was only $32M (operating cash flow $285M less a stepped-up $253M of capex versus $137M in Q1), and GAAP results are still loss-making at the TTM level (net margin -9.3%, EPS -$2.056). Analyst consensus is anchored at Hold (15 Buy / 20 Hold / 1 Sell), which is an accurate description of how the market is treating it: interesting, not yet proven.

Revenue is not the problem - it is inflecting modestly upward after the portfolio contraction. Post-divestiture quarterly revenue ran $2.753B (Q4 2024) -> $2.625B -> $2.810B -> $2.835B -> $2.974B -> $2.701B -> $2.960B (Q2 2026), with YoY growth improving from +2.9% in Q1 2026 to +5.3% in Q2 2026 (management cited +5% organic, with Advanced Surgery +12% to $331M, Medical Products & Therapies $2.08B +5% organic, Healthcare Systems & Technologies $801M +4%). Earnings quality, not demand, is the issue, and it is largely a one-off story. GAAP diluted EPS went -$0.089 (Q3 2025) -> -$2.16 (Q4 2025) -> -$0.03 (Q1 2026) -> +$0.24 (Q2 2026). Q4 2025 was a kitchen-sink quarter - operating income -$729M, net loss -$1.128B, gross margin collapsing to 19.4% - and it is the single biggest reason every trailing metric looks broken. Strip it out and the underlying trajectory is improving: gross margin 33.5% (Q3 2025) -> 33.0% (Q1 2026) -> 34.9% (Q2 2026), and Q2 2026's $217M operating income (7.3% margin) is the best non-Q4-2023 quarter in the entire three-year data set. Cash flow is genuinely mixed: H1 2026 operating cash flow of $498M demolished H1 2025's $24M, but Q2 2026 free cash flow was only $32M because capex jumped. The balance sheet is quietly repairing - long-term debt down from $9.473B (2025-12-31) to $8.615B (2026-06-30), cash up to $2.15B, net debt roughly $6.5B against $6.2B of equity. Verdict: an early-stage operating inflection, not a structural decline - but one still obscured by charges and weak cash conversion. Note the deterministic score flags that YoY comparisons spanning the divestiture are distorted, so treat the growth legs with some caution.

GAAP P/E is meaningless (-11.67 on TTM EPS of -$2.056), so ignore it. On the numbers that matter, BAX is cheap-to-fair as of 2026-09-13: $23.80 divided by ~$2.05 of forward adjusted EPS is roughly 11.6x, versus a 5-year average P/E of 20.45x (caveat: only 2 years of data used, and that average is built on a much higher GAAP earnings base), and 1.07x sales against a 5-year average P/S of 2.05x. Price-to-book is 1.98x. The trailing EV/EBITDA of 26.5x looks alarming but is an artifact of the Q4 2025 charge; on roughly $2.3B of normalized EBITDA against ~$18.8B of enterprise value, the multiple is nearer 8-9x. The discount is real but partly deserved: 30.1% TTM gross margin is well below medtech norms, ROIC is -1.8% (the company is not currently earning its cost of capital), and net debt of ~$6.5B sits against $6.2B of equity. Cheap versus its own history on sales and forward earnings; not a bargain on GAAP quality.

The market is valuing BAX off adjusted earnings but refusing to pay a normal medtech multiple for them. At $23.80 and ~$2.05 of forward adjusted EPS you are paying ~11.6x for a business that guided to $1.95-$2.15 for FY2026 and grew organic revenue 5% last quarter - a 7-9 point discount to the stock's own 5-year average P/E. That discount is the market saying 'show me cash.' If H2 2026 delivers the guidance with gross margin holding above 34% and free cash flow inflecting back toward the $400M+ quarterly run-rate seen in Q4 2025, the multiple has room toward 13-15x, i.e. $27-$31. If capex stays at Q2's $253M quarterly pace and the tariff refund proves to be exactly what it sounds like, EPS growth will not convert to cash, and the stock stays range-bound between roughly $20 and $26. In other words, the current price already embeds a lot of skepticism about the turnaround - the question is whether that skepticism is a margin of safety or an accurate read.

As of 2026-09-13, BAX's RSI(14) stood at 35.08 - weak, approaching but not at oversold - with price 7.59% below its 20-day SMA (roughly $25.76) and 4.49% below its 50-day (roughly $24.92), yet still 16.25% above its 200-day SMA (roughly $20.47). That combination - short-term breakdown inside a longer-term uptrend - reads as a corrective pullback, not a trend reversal: the stock is +14.09% over three months and +36.78% over six, so the one-week -7.86% and one-month -11.69% moves are giving back part of a big run rather than starting a new downtrend. Entry-timing implication: an RSI in the mid-30s is not yet a washed-out signal, and buying into a stock that just lost 8% in a week while sitting 16% above its 200-day is poor risk/reward. A stabilization back above RSI 40 plus a reclaim of the 50-day near $24.90 would be the first confirmation; the 200-day near $20.50 is where the risk/reward genuinely improves.

• Interest rates and refinancing cost: Baxter carries $8.615B of long-term debt (D/E 1.558) and net debt of roughly $6.5B. Even with a low 0.595 beta, the equity story is a multi-year margin-recovery narrative that is highly sensitive to the discount rate applied to future cash flows, and every dollar of deleveraging is worth more when rates are high.
• Tariffs and input-cost inflation: management explicitly credited a non-recurring tariff refund in the Q2 2026 guidance raise, while ongoing tariff friction and high-cost inventory layers keep gross margin compressed at 30.1% TTM. This is a direct, recurring threat to the margin-recovery thesis.
• Hospital capital spending and elective procedure volumes: Advanced Surgery (+12% organic, $331M) and Healthcare Systems & Technologies ($801M, +4% organic) are levered to procedure volumes and hospital capex budgets. Demand has been resilient, but a hospital capital-budget slowdown would hit the higher-margin equipment lines first.
• MedTech sector rotation and healthcare-system pricing scrutiny: group purchasing organizations and hospital systems continue to press device and consumable pricing, which caps how much of the GPS cost savings can fall through to the operating line.
• Structural manufacturing footprint and IV-solutions competition: Baxter's 30% gross margin is not purely cyclical - it reflects a low-margin sterile fluids/IV mix and a heavy fixed manufacturing base. Even a successful turnaround likely leaves Baxter at a lower gross margin than most medtech peers.

• Q3 2026 earnings (expected late October 2026): the first real checkpoint on whether the raised FY2026 guidance (3-4% reported growth, $1.95-$2.15 adjusted EPS) is tracking, and specifically whether gross margin holds or builds on Q2's 34.9% and whether free cash flow recovers from the weak $32M in Q2 2026.
• Continued debt paydown and portfolio optimization: long-term debt already fell from $9.473B (2025-12-31) to $8.615B (2026-06-30) while cash rose to $2.15B. Pushing net debt meaningfully below $6B would be a genuine re-rating trigger given the leverage overhang.
• Advanced Surgery momentum and GPS cost-savings delivery: Advanced Surgery grew 12% organic on hemostats and sealants; sustained double-digit growth in the highest-margin segment is the cleanest path to margin expansion that does not depend on one-offs.
• Analyst estimate and target revisions: post-Q2 target hikes to $28-$29 (TD Cowen, Stifel, Citigroup) sit above the $25 average consensus target. If Q3 confirms the trajectory, consensus targets and the 15 Buy ratings could migrate higher, providing a sentiment tailwind.

• Earnings quality and one-off dependence: the Q2 2026 beat and guidance raise leaned partly on a non-recurring tariff refund, and Q4 2025 showed how fast GAAP results can break (-$729M operating income, -$1.128B net loss). If the underlying improvement is thinner than the headline suggests, the current 11.6x forward multiple is not as cheap as it looks.
• Cash conversion: Q2 2026 free cash flow was only $32M on $285M of operating cash flow because capex spiked to $253M (versus $137M in Q1 2026 and $149M in Q2 2025). TTM FCF of ~$678M is a ~5.5% yield on market cap - acceptable, but not enough to both delever and fund growth if capex stays elevated.
• Leverage against a negative-Return business: $8.615B of long-term debt against $6.206B of equity (D/E 1.558) while ROIC is -1.8% and ROE is -15.6%. The company is not currently earning its cost of capital, which means the equity is a bet on the fix working.
• Structurally low gross margin: 30.1% TTM gross margin (34.9% in the best recent quarter) is far below typical medtech levels. If manufacturing overhead, high-cost inventory layers, and tariffs keep it there, EPS growth will be capped regardless of revenue growth.
• No income cushion and extended technicals: the dividend yield is 0.153% - effectively gone - so shareholders are paid nothing while waiting for the turnaround. Combined with price sitting 16.25% above the 200-day SMA as of 2026-09-13, a failure to deliver on Q3 creates disproportionate downside.

Baxter is a legitimate but unproven turnaround, not a broken business and not a bargain bin steal. The positives are real: ~5% organic growth, a Q2 2026 beat with raised FY2026 guidance, the best operating-margin quarter outside Q4 2023, roughly $1.5B of net debt paid down since the start of 2025, revenue growth re-accelerating from +2.9% to +5.3%, and a stock at ~11.6x forward adjusted EPS against a 20.45x 5-year average P/E. The negatives are equally real: 30% gross margin, negative ROIC, GAAP losses, an earnings beat that leaned on a non-recurring tariff refund, free cash flow of just $32M last quarter, and a chart that is 16% above its 200-day after a 37% six-month run. At $23.80 on 2026-09-13 with RSI at 35 and analysts at Hold, this is a position you build patiently on weakness toward the $20-$21 area, not something to chase. Directional lean: Neutral - the risk/reward is roughly balanced here, and the case for owning it only becomes compelling if Q3 2026 shows gross margin above 34% AND free cash flow converting back toward $300-400M.

Applied 13x to forward adjusted EPS of ~$2.05 (the midpoint of the raised FY2026 guidance of $1.95-$2.15, which also matches the next-FY consensus estimate of $2.054) - a multiple below the 20.45x 5-year average P/E but above the ~11.6x the stock traded at on 2026-09-13, giving partial credit for 5% organic growth, margin recovery from 30.1% toward the mid-30s, and ~$1.5B of net debt reduction against a still-structurally-low 30% gross margin. Cross-checked with a normalized free-cash-flow yield (~6% required return on ~$800M of capex-normalized FCF implies ~$13.3B equity, or ~$25.80/share) and ~9x EV/EBITDA on ~$2.3B of normalized EBITDA (implying ~$27.50/share), both of which bracket the $26.50 figure.